Ratings by Stifel (Samimy Annabel)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/20/2026 | Eupraxia Pharmaceuticals | EPRX | New Coverage | Buy (N/A) |
6.29 (6.25) |
-0.64% | Details | |
| 2/24/2026 | Palvella Therapeutics | PVLA | Maintain | Buy (N/A) |
|
Details | ||
| 11/24/2025 | Palvella Therapeutics | PVLA | Maintain | Buy (N/A) |
|
Details | ||
| 11/5/2025 | Palvella Therapeutics | PVLA | Maintain | Buy (N/A) |
|
Details | ||
| 10/9/2025 | Inventiva SA | IVA | Maintain | Buy (Buy) |
|
Details | ||
| 9/24/2025 | Palvella Therapeutics | PVLA | Maintain | Buy (N/A) |
|
Details | ||
| 8/19/2025 | Viking Therapeutic | VKTX | Maintain | Buy (N/A) |
|
Details | ||
| 7/24/2025 | Viking Therapeutic | VKTX | Maintain | Buy (Buy) |
|
Details | ||
| 4/2/2025 | Inventiva SA | IVA | Maintain | Buy (N/A) |
|
Details | ||
| 3/31/2025 | Palvella Therapeutics | PVLA | Maintain | Buy (N/A) |
|
Details | ||
| 3/26/2025 | Palvella Therapeutics | PVLA | New Coverage | Buy (N/A) |
27.87 (129.84) |
365.88% | Details | |
| 3/26/2025 | Palvella Therapeutics | PVLA | New Coverage | Buy (N/A) |
27.87 (27.87) |
0% | Details | |
| 11/22/2024 | Inventiva SA | IVA | Maintain | Buy (N/A) |
|
Details | ||
| 10/14/2024 | Inventiva SA | IVA | Maintain | Buy (N/A) |
|
Details | ||
| 9/26/2024 | Inventiva SA | IVA | Maintain | Buy (N/A) |
|
Details | ||
| 3/26/2024 | Viking Therapeutic | VKTX | Maintain | Buy (N/A) |
|
Details | ||
| 2/27/2024 | Viking Therapeutic | VKTX | Maintain | Buy (N/A) |
|
Details | ||
| 2/16/2024 | Inventiva SA | IVA | Maintain | Buy (N/A) |
|
Details | ||
| 2/14/2024 | Viking Therapeutic | VKTX | Maintain | Buy (N/A) |
|
Details | ||
| 3/28/2023 | Viking Therapeutic | VKTX | Maintain | Buy (N/A) |
|
Details | ||
| 3/17/2023 | Inventiva SA | IVA | New Coverage | Buy (N/A) |
4.03 (3.46) |
-14.14% | Details | |
| 3/17/2023 | Viking Therapeutic | VKTX | New Coverage | Buy (N/A) |
10.68 (37.87) |
254.59% | Details |
